trans
conference appearances
trans
contact
impressum
legal notice
print this page
BioSolveIT
The Premier Scientific Solution Provider
BioSolveIT attends various conferences and exhibitions, primarily as speakers, where we will be pleased to meet you and answer any questions you may have about BioSolveIT, our products and services and our most recent developments.

BioSolveIT's next public appearance will be at:
August 22 - 26, 2010
240th ACS National Meeting & Exposition
Boston, MA, United States
23.08.
Lightning-fast 3D-shape and feature-based virtual screening
C. Lemmen
show abstract
Descriptor-based similarity searches are known to be extremely fast and sutable for high throughput virtual screening. Whereas shape-based methods are consitered to be more accurate but significantly slower. We have combined these two approaches to gain the better of both worlds, the speed of the descriptor-based search and the accuracy of the shape matching. Application examples and results of benchmark studies will be presented.
 
25.08.
Recent advances in computational fragment-based lead discovery
C. Detering, H. Claußen, M. Gastreich, M. Lilienthal, and C. Lemmen
show abstract
It has frequently been shown in the course of the last years that using fragments as a starting point for buildup is a very sensible approach to finding promising new lead structures. Fragment Growing, linking and merging have been employed to successfully improve binding affinity of new chemical entities. Moreover, searching fragment spaces for novel entities that meet a certain pharmacophore or synthetic criteria is a very powerful means of quickly ascertain new lead compounds with different scaffolds and improved binding motifs. In this contribution we bring an overview of 2D and 3D methods capable of using fragments to find, change or improve new chemical entities, scaffold hop across compound classes, and the sensible design of the underlying fragment spaces. We show some improvements we recently introduced to excel these apporaches. Some recent applications in the industry that verify these methods will be shown.
 
25.08.
Importance of pharmaceutically relevant benchmark data
C. Lemmen, . Gastreich, C. Detering, and P. Oledzki
show abstract
As a methods developer it is highly desirable to have high-quality benchmark data available for testing. Unfortunately the number and quality of such data sets that are pblished and freely available is quite limited. Also if such data is available, methods developers may use the data for training and testing. It was therefore quite valuable for the community to have a data-set that was not only well prepared and standardized such as to be applicable for various computer programs, but also to be able to preform blind studies which prevented the developers from overfitting their methods in an effort to improve performance. We will share our experience from application studies based on such data and explain in which way this guided the further development of our docking technology.
 

Last modified Monday, 05. Jul 2010 13:57 CEST by WebMaster